Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer.
Journal Article (Journal Article;Review)
Chronic kidney disease is prevalent, affecting more than one in ten adults. In this population, metabolic acidosis is considered a key underlying pathophysiological feature, tying together bone mineral disorders, sarcopenia, insulin resistance, vascular calcification, pro-inflammatory and pro-thrombotic states. This review aims to address the paucity of literature on alkalinizing agents, a promising treatment option that has known adverse effects.
Full Text
Duke Authors
Cited Authors
- Copur, S; Sag, AA; Afsar, B; Rossignol, P; Covic, A; Kanbay, M
Published Date
- December 2020
Published In
Volume / Issue
- 52 / 12
Start / End Page
- 2311 - 2320
PubMed ID
- 32661618
Electronic International Standard Serial Number (EISSN)
- 1573-2584
Digital Object Identifier (DOI)
- 10.1007/s11255-020-02563-2
Language
- eng
Conference Location
- Netherlands